Industrial Biotransformations

Trypsin
Pig Pancreas
2) Remarks
● The precursor pre-pro insulin (PPI) is directly produced by fermentation of E. coli using the
recombinant DNA-technology.
3) Flow scheme
Not published.
4) Process parameters
conversion: > 99.9 %
yield: > 65 %
selectivity: > 65 %
reactor type: batch
reactor volume: 10,000 L
capacity: > 0.5 t · a –1
residence time: 6 h
space-time-yield: 2.1 g · L –1 ·d –1
enzyme activity:
enzyme supplier:
80 U · L –1
reaction solution
Calbiochem, USA
start-up date: 1998
production site: Sanofi Aventis, Germany
company: Sanofi Aventis, France
5) Product application
● See next step of process on page 346.
6) Literature
EC 3.4.21.4
● Frank, B.H., Chance, R.E. (1983) Two routes for producing human insulin utilizing recombinant
DNA technology, Münch. Med. Wschr. 125, 14–20
● Jørgensen, L.N., Rasmussen, E., Thomsen, B. (1989) HM(ge), Novo’s biosynthetic insulin;
Med. View. III, No. 4, 1–7
● Ladisch, M.R., Kohlmann, K.L. (1992) Recombinant human insulin, Biotechnol. Prog. 8, 469–
478
353